Role of DNA-detection-based tools for monitoring the soil-transmitted helminth treatment response in drug-efficacy trials.
Javier Gandasegui, María Martínez-Valladares, Berta Grau-Pujol and 8 more
PLoS Neglected Tropical Diseases · 2020
doi:10.1371/journal.pntd.0007931 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
More than 1 billion people have been reported to be infected with at least one soil-transmitted helminth (STH) worldwide, according to the last published report of the World Health Organization (WHO). WHO guidelines for STH control mainly encompass periodic administration of benzimidazoles (albendazole or mebendazole) to at-risk people of the endemic areas. However, extended use of benzimidazoles could entail a great selection pressure for parasitic-resistant strains. In veterinary medicine, anthelmintic resistance in gastrointestinal nematodes has been developed in response to their excessive use, and it is currently considered a serious threat to livestock health and welfare. In humans, the estimated efficacy of albendazole and mebendazole against Trichuris trichiura has been observed to significantly decrease over time. This observed decrement in drug efficacy could be due to the development of anthelmintic resistance (among other reasons such as drug quality and administration, the increasing of drug-efficacy studies, improvements in sensitivity of diagnostic tools after treatment, etc) after years of mass drug-administration campaigns, which is one of the major concerns in STH control. Monitoring anthelmintic efficacy trials have been traditionally done by microscopic approaches, although it is well known that microscopy’s sensitivity may be insufficient in this context. We think that DNA-detection–based tools represent an accurate alternative to parasitological methods, and they should be evaluated and validated not only for monitoring worm burden before and after treatment but also for detecting genetic markers related to anthelmintic resistance.
Abstract licence: CC BY
References24
- 7.
- 11.
- 14.
21 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.